RxDoctor Payments Data

Mai Yousef, MD

Family Medicine · Pittsburgh, PANPI 1437119914

Payments from drug & device makers

$1,728in general payments, 2019–2025

Across 35 payments — averaging $49.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$478
  • Novo Nordisk$288
  • AbbVie$276
  • Otsuka America Pharmaceutical, Inc.$246
  • Bayer$125
  • Amgen$109
  • plus $206 from 4 others

What the payments were for

  • Food & beverage$1,728100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,728 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$120,949
Medicare patients
159
Services billed
3,207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$118,751
JardianceEmpagliflozin89$86,554
OzempicSemaglutide77$78,341
XareltoRivaroxaban55$38,749
AbrysvoRsv Vacc, Pref A And Pref B/Pf78$24,749
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$22,626
MyrbetriqMirabegron20$15,829
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,782
EntrestoSacubitril/Valsartan11$13,427
MounjaroTirzepatide11$13,221
Spiriva RespimatTiotropium Bromide23$11,989
Breo ElliptaFluticasone/Vilanterol24$9,916
FarxigaDapagliflozin Propanediol11$8,665
Tresiba Flextouch U-100Insulin Degludec16$8,207
JanuviaSitagliptin Phosphate12$6,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$288$78,34177 claims
Lilly USA, LLCMounjaro$92$13,22111 claims
AstraZenecaFarxiga$478$8,66511 claims
AbbVieLinzess, Synthroid$276$8,08465 claims
MerckJanuvia$86$6,69212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →